You are here

Sustained MR with Interferon Alfa Maintenance After Induction Therapy With Imatinib + Interferon Alfa in CML

sandy craine's picture
Submitted by sandy craine on Thu, 11/02/2010 - 1:47pm
JCO Early Release, published online ahead of print Feb 8 2010 Journal of Clinical Oncology, 10.1200/JCO.2009.25.5075

JCO Early Release, published online ahead of print Feb 8 2010
Journal of Clinical Oncology, 10.1200/JCO.2009.25.5075

Driving away Big Pharma is not NICE or clever:

sandy craine's picture
Submitted by sandy craine on Wed, 10/02/2010 - 6:58pm
Driving away Big Pharma is not NICE or clever Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?

Driving away Big Pharma is not NICE or clever
Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?

Webcast- LLSociety. 'Current treatment Options in CML-Progress in Research'

sandy craine's picture
Submitted by sandy craine on Thu, 04/02/2010 - 12:34pm
The Leukaemia and Lymphoma Society, US, have produced another excellent webcast 'Current treatment Options in CML-Progress in Research' with the following speakers: Michael J. Mauro, MD

The Leukaemia and Lymphoma Society, US, have produced another excellent webcast 'Current treatment Options in CML-Progress in Research' with the following speakers:

Michael J. Mauro, MD

Vaccine in CML- Abstract AACRJournals

sandy craine's picture
Submitted by sandy craine on Mon, 25/01/2010 - 11:14am
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

Cord blood stem cell transplant hopes lifted

sandy craine's picture
Submitted by sandy craine on Tue, 19/01/2010 - 12:34pm
Cord blood stem cell transplant - hopes lifted Matching donors cannot always be found, despite extensive registries A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.

Cord blood stem cell transplant - hopes lifted

Matching donors cannot always be found, despite extensive registries
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.

Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase In

sandy craine's picture
Submitted by sandy craine on Tue, 12/01/2010 - 12:14pm
Cancer News Article Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.[1]

Cancer News Article

Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML Refractory to First- and Second-generation Kinase Inhibitors
Researchers involved in an international multicenter Phase I study have reported that danusertib (PHA-739358) produces responses in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.[1]

Pages